Melanoma

New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma

2023-01-10

  • Study

    Phase III, multicenter, randomized, double-blind trial
    Previously untreated unresectable stage IIIc or stage IV melanoma
    Atezolizumab (n=256) vs. PBO + vemurafenib + cobiventinib (n=258)

  • Efficacy

    mOS: 39.0 vs 25.8 mos, HR:0.84, p=0.10

  • Safety

    Grade3 AEs: increased lipase (23% vs. 22%), increased CK (22% vs. 18%), increased alanine aminotransferase (14% vs. 9%).


    • Lancet Oncology,2023 JAN, 24 (1): p33 – 44

    Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomized, phase 3 study

    http://doi.org/10.1016/S1470-2045(22)00687-8

    Reviewed by Elvin Chalabiyev, MD on Jan 10, 2023